T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
REVG
1101
DELISTED
REV Group
REVG
| $26.1M | ﹤0.01% |
1,814,576
+4,100
| +0.2% | +$50.1K |
|
1102
Quest Diagnostics
DGX
$26.1B
| $26.1M | ﹤0.01% |
256,700
+730
| +0.3% | +$70.1K |
|
|
CARO
1103
DELISTED
Carolina Financial Corp.
CARO
| $26M | ﹤0.01% |
741,538
-10,021
| -1% | -$357K |
|
1104
Atkore
ATKR
$3.17B
| $26M | ﹤0.01% |
1,005,161
-307,878
| -23% | -$7.52M |
|
1105
Conduent
CNDT
$243M
| $26M | ﹤0.01% |
2,710,953
-2,276,067
| -46% | -$24.6M |
|
1106
RH
RH
$3.43B
| $25.9M | ﹤0.01% |
224,243
-1,500,205
| -87% | -$155M |
|
1107
Mid-America Apartment Communities
MAA
$15.6B
| $25.8M | ﹤0.01% |
218,856
-10,353
| -5% | -$1.17M |
|
1108
Dover
DOV
$27.9B
| $25.6M | ﹤0.01% |
255,592
+972
| +0.4% | +$93.2K |
|
1109
Supernus Pharmaceuticals
SUPN
$2.75B
| $25.5M | ﹤0.01% |
771,785
+1,677
| +0.2% | +$57.5K |
|
1110
Hormel Foods
HRL
$13.5B
| $25.5M | ﹤0.01% |
629,933
-16,157
| -3% | -$655K |
|
1111
Arista Networks
ANET
$263B
| $25.5M | ﹤0.01% |
1,571,648
+55,056
| +4% | +$953K |
|
1112
Assured Guaranty
AGO
$3.33B
| $25.2M | ﹤0.01% |
597,857
-301
| -0.1% | -$13.3K |
|
1113
International Seaways
INSW
$4.69B
| $25.1M | ﹤0.01% |
1,321,208
-27,236
| -2% | -$504K |
|
1114
Extra Space Storage
EXR
$31.4B
| $25M | ﹤0.01% |
236,062
+1,800
| +0.8% | +$189K |
|
1115
GoDaddy
GDDY
$11.6B
| $25M | ﹤0.01% |
356,602
+31,781
| +10% | +$2.4M |
|
1116
Iron Mountain
IRM
$37.4B
| $25M | ﹤0.01% |
797,705
-30,072
| -4% | -$985K |
|
|
GHDX
1117
DELISTED
Genomic Health, Inc.
GHDX
| $24.9M | ﹤0.01% |
428,533
+5,279
| +1% | +$313K |
|
|
SIX
1118
DELISTED
Six Flags Entertainment Corp.
SIX
| $24.8M | ﹤0.01% |
499,865
+2,494
| +0.5% | +$129K |
|
1119
Lincoln National
LNC
$8.53B
| $24.7M | ﹤0.01% |
382,484
-3,375
| -0.9% | -$216K |
|
1120
James River Group Holdings
JRVR
$205M
| $24.6M | ﹤0.01% |
525,409
+2,630
| +0.5% | +$114K |
|
1121
Oil-Dri
ODC
$1.28B
| $24.3M | ﹤0.01% |
1,426,954
+61,336
| +4% | +$957K |
|
1122
Madrigal Pharmaceuticals
MDGL
$12.1B
| $24.2M | ﹤0.01% |
230,870
-30,667
| -12% | -$3.28M |
|
|
RTEC
1123
DELISTED
Rudolph Technologies Inc
RTEC
| $24.2M | ﹤0.01% |
875,686
-8,869
| -1% | -$216K |
|
1124
CorVel
CRVL
$3.17B
| $24.2M | ﹤0.01% |
832,800
+92,775
| +13% | +$2.28M |
|
1125
Fate Therapeutics
FATE
$309M
| $24.1M | ﹤0.01% |
1,187,839
-60,943
| -5% | -$1.1M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.